BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28633317)

  • 1. Discussion: The FDA is Unprepared for Personalized Medicine.
    Tabarrok A
    Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends.
    Liu Q; Ahadpour M; Rocca M; Huang SM
    AAPS J; 2021 Apr; 23(3):54. PubMed ID: 33846878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexibility in the FDA approach to orphan drug development.
    Hunter NL; Rao GR; Sherman RE
    Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
    [No Abstract]   [Full Text] [Related]  

  • 4. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
    Issa AM; Thorogood A; Joly Y; Knoppers BM
    Genet Med; 2019 Mar; 21(3):542-544. PubMed ID: 29988078
    [No Abstract]   [Full Text] [Related]  

  • 5. From Molecule to Patient and Ways to Get the Dose Precisely Right.
    Vinks AA
    Clin Pharmacol Ther; 2019 Mar; 105(3):534-537. PubMed ID: 30773626
    [No Abstract]   [Full Text] [Related]  

  • 6. Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public Health.
    Zuckerman DM
    Am J Public Health; 2021 Jun; 111(6):1065-1069. PubMed ID: 33950730
    [No Abstract]   [Full Text] [Related]  

  • 7. Discussion: The role, position, and function of the FDA-The past, present, and future.
    Fleming TR; Demets DL; McShane LM
    Biostatistics; 2017 Jul; 18(3):417-421. PubMed ID: 28633307
    [No Abstract]   [Full Text] [Related]  

  • 8. Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.
    Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
    Alcohol Clin Exp Res; 2020 Jan; 44(1):23-35. PubMed ID: 31803968
    [No Abstract]   [Full Text] [Related]  

  • 9. [Significance of genetic tests in the era of personalized medicine].
    Molnár JM; Magyarósi S; Németh G
    Magy Onkol; 2013 Mar; 57(1):16-20. PubMed ID: 23573517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
    Jørgensen JT; Hersom M
    Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can precision medicine reduce overdiagnosis?
    Hunt S; Jha S
    Acad Radiol; 2015 Aug; 22(8):1040-1. PubMed ID: 26100198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An appraisal of drug development timelines in the Era of precision oncology.
    Jardim DL; Schwaederle M; Hong DS; Kurzrock R
    Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulations, economics hindering adoption of personalized medicine.
    Thompson CA
    Am J Health Syst Pharm; 2011 Mar; 68(5):372-4. PubMed ID: 21330674
    [No Abstract]   [Full Text] [Related]  

  • 14. Dearth of clinically useful diagnostics limits growth of personalized medicine.
    Cohen J
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):527-9. PubMed ID: 22220302
    [No Abstract]   [Full Text] [Related]  

  • 15. Developing Pharmacologic Treatments for Eosinophilic Esophagitis: Draft Guidance from the United States Food and Drug Administration.
    Lyons E; Donohue K; Lee JJ
    Gastroenterology; 2019 Aug; 157(2):275-277. PubMed ID: 31022402
    [No Abstract]   [Full Text] [Related]  

  • 16. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine.
    Evans JP; Watson MS
    JAMA; 2015 Feb; 313(7):669-70. PubMed ID: 25560537
    [No Abstract]   [Full Text] [Related]  

  • 19. Messing with home brews.
    Nat Biotechnol; 2007 Mar; 25(3):262. PubMed ID: 17344864
    [No Abstract]   [Full Text] [Related]  

  • 20. Toward a Personalized Use of Paclitaxel.
    Russo GL
    Recent Pat Anticancer Drug Discov; 2019; 14(4):296-297. PubMed ID: 31920185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.